The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
Travel, Accommodations, Expenses - MedImmune
Patient-reported outcomes (PROs) in patients with urothelial carcinoma (UC) treated with durvalumab (second-line or above) in phase 1/2 dose-escalation study 1108.
 
Peter H. O'Donnell
Stock and Other Ownership Interests - Allergan
Honoraria - Algeta ASA; American Medical Forum; Astellas Pharma; AstraZeneca; Genentech/Roche; Harrison Consulting Group; Inovio Pharmaceuticals; Janssen Biotech; Kantar Health; Merck; Novartis; Parexel; Quintiles; Seagen; Xcenda
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Named as co-inventor on a pending patent for a genomic prescribing system for medication prescribing.
Expert Testimony - TERA; Triage Cancer
Travel, Accommodations, Expenses - Merck
Other Relationship - Advance Medical
 
Hendrik-Tobias Arkenau
No Relationships to Disclose
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Michael Ong
Honoraria - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Johnson & Johnson; Merck
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Alexandra Drakaki
No Relationships to Disclose
 
Alexander I. Spira
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Sanofi
Speakers' Bureau - AstraZeneca/MedImmune; Sanofi
Research Funding - Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst)
 
Michael S. Gordon
Stock and Other Ownership Interests - Caremission; WCCT Global
Consulting or Advisory Role - Castle Biosciences; Deciphera; RedHill Biopharma; TRACON Pharma
Research Funding - Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); BeiGene (Inst); BiolineRx (Inst); Calithera Biosciences (Inst); CanBas (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Hengrui Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); SynDevRx (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Arnold Degboe
Employment - AstraZeneca
 
Ashok Kumar Gupta
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Pralay Mukhopadhyay
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Wenmei Huang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Shaad Essa Abdullah
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
 
Natasha Angra
No Relationships to Disclose
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - EMD Serono
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Foundation Medicine; Genentech
Speakers' Bureau - Astellas Medivation; Dendreon; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Janssen
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche